Mint Explainer | Can the government make life-saving drugs cheaper? | Today’s news

However, Amit Panigrahi, a partner at Kochhar & Co.’s intellectual property practice, said the decision could create regulatory uncertainty. “While the court has protected drug companies from arbitrary court mandates, the legal confirmation that the government can override a patent based only on pricing data creates a regulatory risk that could make companies more cautious about investing in or launching expensive patented drugs in India,” he said.